Policy & Regulation
McKesson to acquire Precision Medicine Group for approximately USD2.25bn
25 August 2026 - Healthcare services company McKesson Corporation (NYSE:MCK) announced on Tuesday that it has signed a definitive agreement to acquire Precision Medicine Group, a global provider of cl...
CDT signs SAFE note with Pep'd to expand US peptide market exposure
25 August 2026 - US biopharmaceutical development company CDT Equity Inc. (NASDAQ: CDT) said on Tuesday it has entered into a SAFE note with Pep'd Inc., a US-based peptide business.The instrument...
FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia
25 August 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) for the treatmen...
Astellas doses first patient in Phase 3 study of ASP2138
25 August 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Monday that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chem...
Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia
25 August 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996.HK) announced on Monday that the Phase I ATTRACT study of its proprietary ATG-201, a CD19/CD3 bispecific T-ce...
United Therapeutics wins FDA acceptance for ralinepag PAH filing
24 August 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) said on Monday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for ralinepag t...